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Objective: Management of lymph nodes in radiotherapy for prostate cancer is an issue for
curative intent. To ﬁnd the inﬂuence of lymph nodes, patients with T1–T3 prostate cancer
and surgically conﬁrmed negative nodes were treated with radiotherapy.
Methods: After lymphadenectomy, 118 patients received photon beam radiotherapy with
66 Gy to the prostate. No adjuvant treatment was performed until biochemical failure.
After failure, hormone therapy was administered. Follow-up period was 57 months
(mean).
Results: Biochemical failure occurred in 47 patients. Few failures were observed in
patients with low (24%) and intermediate risks (14%). In contrast, 64% of high-risk
patients experienced failure, 97% of whom showed until 36 months. Most patients with
failure responded well to hormone therapy. After 15 months (mean), a second biochemi-
cal failure occurred in 21% of patients who had the ﬁrst failure, most of them were high
risk. Factors involving failure were high initial and nadir prostate-speciﬁc antigen,
advanced stage, short prostate-speciﬁc antigen-doubling time and duration between radi-
ation and ﬁrst failure. Failure showed an insufﬁcient reduction in prostate-speciﬁc antigen
after radiotherapy. Factor for second failure was prostate-speciﬁc antigen-doubling time at
ﬁrst failure.
Conclusions: Half of high-risk patients experienced biochemical failure, indicating one of
the causes involves factors other than lymph nodes. Low-, intermediate- and the other
half of high-risk patients did not need to take immediate hormone therapy after radiother-
apy. After failure, delayed hormone therapy was effective. Prostate-speciﬁc antigen par-
ameters were predictive factors for further outcome.
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INTRODUCTION
Localized prostate cancer has been treated with various
methods, and the results were improved gradually. Of these
technologies, surgical and radiological treatments play a
leading part in the ﬁeld (1). An important issue in radiother-
apy is conjecture of the status of regional lymph nodes.
There are many guidelines for the estimation of possible
invasion in the lymph nodes, where they are estimated from
the stage, prostate-speciﬁc antigen (PSA) and histological
ﬁndings from biopsy (2,3). The predictive score obtained by
assuming these guidelines, however, may be indeﬁnite (4,5).
On the basis of the uncertainty for predicting invasion,
whole pelvic radiotherapy has been discussed to improve
PSA-free survival (6). In order to exclude the inﬂuence of
regional lymph nodes on whether invasion may be present,
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The present study was undertaken ﬁrst to perform the lym-
phadenectomy in patients with localized prostate cancer.
Thereafter, the patients with N0 received radiotherapy alone.
PATIENTS AND METHODS
PATIENTS
Between January 1999 and January 2006, pelvic lymphade-
nectomy was performed in 168 patients with T1–T3 prostate
cancer who selected rather non-aggressive treatment at Asahi
General Hospital. For lymphadenectomy, the obturator, exter-
nal and internal iliac lymph nodes were removed via an
abdominal incision or laparoscopic surgery. Of these cases,
144 cases (86%) showed negative ﬁndings. Stage was deﬁned
with UICC TNM classiﬁcation (6th edn, 2002). Risk was
classiﬁed into low (T1bc and T2a, ,10 ng/ml of PSA and
6 of Gleason score), intermediate (T2b,c or 10–20 ng/ml
of PSA or 7 of Gleason score) or high ( T3 or 20 ng/ml
of PSA or 8 of Gleason score) according to NCCN criteria
(7). After radiotherapy, no adjuvant hormone therapy was
administered until biochemical failure. PSA was determined
every 3 or 6 months, and when elevation occurred, duration
of determination was shortened. Biochemical failure was
judged with Phoenix criteria (elevated 2 ng/ml of PSA or
more from baseline, or clinical relapse) (8). Some patients
with biochemical failure experienced second failure, which
was judged with increase in PSA from baseline. Prostate
biopsy was carried out with 8–12 cores via a perineal route.
Gleason score was determined according to ISUP (9).
Records of all patients were collected in June 2009
(follow-up, mean 57 months, median 52 months and range
9–119 months). After biochemical failure, most patients
received hormone therapy with luteinizing hormone–releasing
hormone agonist and 80 mg of bicalutamide daily until the
hormone therapy failed. Evaluation for hormone therapy was
determined from response to the therapy: decrease of 50%
from baseline in the PSA (partial response, PR), increase of
25% from baseline in the PSA (progressive disease, PD) or
change between PR and PD (no change, NC).
PSA KINETICS
PSA was determined as total PSA using AxSYM PSA
Dainapack (Abbot, Tokyo, Japan). PSA-doubling time
(PSA-DT) and velocity were calculated by linear regression.
A slope was obtained by the least-square test with values of
ln PSA (PSA-DT) or those of PSA (velocity) from three or
more points. PSA-DT was obtained from ln 2/slope (10).
Velocity was determined as a difference per year (11).
RADIATION
Conformal radiation with a photon beam at 10 MV was
used with a multileaf collimator (leaves 10 mm at isocenter).
The clinical target volume was the whole prostate and the
planning target volume was created by adding 10 mm anter-
oposterior and lateral margins. A conventional fractionation
of 2 Gy/fraction was administered ﬁve times per week for
66 Gy of total radiation dose.
STATISTICAL ANALYSIS
Overall survival was calculated with the Kaplan–Meier
method. Statistical difference was determined by the
unpaired two-group t-test. Odds ratio was calculated by the
logistic regression analysis. Values of P  0.05 were con-
sidered to be signiﬁcant. All calculations were used with the
StatView program.
RESULTS
BIOCHEMICAL FAILURE
Of 144 patients with negative node, 118 cases received radi-
ation after conﬁrming no distal metastatic disease using bone
scan and abdominal echogram (Table 1). The other 26 cases
were treated surgery or hormonal therapy as chosen by the
patients. Of 118 patients who received radiation, 47 patients
experienced biochemical failure (47 of 118, 40%). Until 36
months after radiation, 42 patients showed biochemical
failure, in which high-risk patients were 34 (81%).
Occurrence of biochemical failure gradually decreased in
number and there was no failure in the remaining patients
after 55 months of the latest failure. Duration of biochemical
failure was mean of 21 months (median 17 months and
range 4–55 months). Rate of failure was 24% in low-risk,
14% in intermediate-risk and 64% in high-risk patients.
The proﬁles of patients with biochemical failure and
failure-free patients were compared (Table 2). Patients with
biochemical failure showed the initial, 12 months later and
nadir PSA values higher than those in failure-free patients
and had a short duration between radiation and nadir.
Inﬂuences on biochemical failure were the initial PSA
values, stage and duration between radiation and nadir
(Table 3). Since PSA-DT is a parameter for tumor growth,
patients with failure were divided by PSA-DT. A positive
relation between duration until nadir and PSA-DT was con-
ﬁrmed (Table 4).
Of 47 patients with biochemical failure, four cases did not
receive an additional hormone therapy because of a slow rise
in PSA. The other 43 patients received hormone therapy
after failure, and responded well as PR, except for one
patient who showed NC temporarily then showed a rapidly
rising PSA and died of prostate cancer 46 months after the
start of radiation.
SECOND BIOCHEMICAL FAILURE AND OUTCOME
Among 47 patients with ﬁrst failure, 10 cases showed a
second increase in PSA (21%). Risks of these 10 patients
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26%). Duration between hormone treatment and the second
failure was mean of 15 months (median 14 months and
range 3–28 months). Factors estimated at ﬁrst failure were
compared between patients with second failure and those
without second failure (Table 5). Patients with second
failure showed shorter PSA-DT, shorter duration between
radiation and ﬁrst failure. These patients were treated with
second-line hormone therapy and/or chemotherapy. Except
for one dead patient, the other nine patients included seven
showing favorable responses and two revealing slowly pro-
gressive disease. These nine patients were alive in June
2009.
Biochemical failure-free survival rate was 52% (61 of
118) at 3 years after radiation. Overall survival rate at 5
years was 87% (Fig. 1). There was only one patient due to
prostate cancer-speciﬁc death. Eight patients died of other
causes except for prostate cancer. There was no complication
due to lymphadenectomy. Concerning the toxicity after radi-
ation according to scoring of Radiation Therapy Oncology
Group, 34% and 5% of early and late Grade 1–2 morbidity,
respectively, showed in the genitourinary system, with 25%
and 5% of early and late Grade 1–2 morbidity, respectively,
in the rectum. No toxicity was developed for Grade 3 or
higher.
DISCUSSION
Survival of patients with prostate cancer after radical treat-
ment is inﬂuenced by the status of the regional lymph nodes.
The number and ﬁndings of invasive nodes correlate with
subsequent outcome (12,13). As a curative treatment with
radiotherapy, aggressive radiation which includes the pelvic
lymph nodes is controversial (14,15). In this discussion, the
adverse effects caused by radiation to the outside of the pros-
tate may be a serious consideration. Alternatively, lymphade-
nectomy before radiation may be proposed. The result from
lymphadenectomy may help to determine the strategy of
further treatment (16). Moreover, this procedure serves to
make a contribution to the relationship between stage and
status of lymph nodes.
Surgical lymphadenectomy causes slight, if any, compli-
cations such as intraoperative injury and postoperative events
(17). The most common complications are lymphocysts or
lymphoceles after radical prostatectomy, but the present
series performed lymphadenectomy alone, so such that
adverse effect may be less likely to occur.
Biochemical failure occurred in more than 50% of patients
with high risk at 5 years after radiotherapy (18). For
extended radiotherapy including pelvic area, biochemical
failure in patients with high risk was 43% at 5 years (19).
Patients receiving radical prostatectomy whose regional
lymph nodes had been removed showed elevation of PSA a
few years later. It was reported that the obturator, external
and internal iliac nodes may be insufﬁcient for the removal
of all suspicious nodes (20,21). The limitation of lymph
node management for curative treatment remains to be
resolved.
The similar biochemical-failure rate was noticed after radi-
ation to patients with N0 in the present study. Together with
the reports, it suggests that patients with high risk already
have the small foci in the distant places. As most biochemi-
cal failure in high-risk patients occurred by 36 months, their
tumors may be rapidly growing with an increase in 2 ng/ml
or more of PSA in this term. Although late recurrence
cannot be ruled out, incidence of biochemical failure slowly
diminished thereafter.
A plausible cause of biochemical failure may be an insuf-
ﬁcient dose of radiation to the prostate. It has been claimed
that a radiation dose of ,70 Gy is insufﬁcient for cure of
prostate cancer (22,23). It is recommended that .72 Gy of
radiation is administered to the prostate of patients with high
risk. Although no cancerous mass in the prostate was found
in the present study, an insufﬁcient dose of radiation cannot
be ruled out.
Table 1. Patients’ characteristics
Age (years)
60 4
61–70 7
71–80 102
81 5
Initial PSA (ng/ml)
,10 60
10.1–20 25
20.1–30 10
30.1–40 5
40.1–50 3
50.1–60 4
60.1 11
Stage
T1b 3
T1c 45
T2a 18
T2b 4
T2c 5
T3a 33
T3b 10
Gleason score
65 6
73 7
82 5
PSA, prostate-speciﬁc antigen.
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with initial PSA, Gleason score and stage, which are well-
known risk factors, and risk classiﬁcation is used from these
factors (24). Patients judged to be high risk might have
progress in unfavorable courses. Duration of time between
radiotherapy and biochemical failure inﬂuences the outcome
(25). Among these factors, the level of PSA is crucial since
patients with .30 ng/ml of PSA showed 20% of PSA-free
rate at 5 years and this rate was independent of other factors
(26). After radiotherapy, insufﬁcient decrease in PSA to
reach a low nadir and a rising pattern of PSA are also con-
sidered as factors for recurrence (27). Patients showed bio-
chemical failure in short duration from radiation have rapidly
growing tumors as estimated from short PSA-DT.
Additional hormone therapy is recommended along with
radiotherapy for patients especially with high risk. Radiation
combined with hormone therapy decreased the biochemical
failure and improved clinical progression-free and cancer-
speciﬁc survival (28). According to literatures, duration of
hormone therapy varies between 4 months and 5 years, or up
Table 2. Patient characteristics, PSA and duration to nadir in patients with or without biochemical failure
Failure (47) Failure-free (71) P value
Age (years) 74, 75 (54–83) 75, 75 (61–82) ns
No lymph node 9.3, 8, (–21) 9.1, 8, (2–28) ns
Risk
Low 8 26
Intermediate 4 25
High 35 20
Initial PSA (ng/ml) 43.0, 23.4 (4.1–290) 11.6, 7.5 (3.1–79.8) 0.0009
12 months PSA (ng/ml)
a 3.1, 1.9 (0.1–14.5) 1.2, 0.8 (0.3–4.8) 0.019
Nadir PSA (ng/ml) 4.3, 1.9 (0.2–51.9) 0.8, 0.5 (0.01–5.5) 0.004
Radiation–nadir (months) 14.3, 12 (2–45) 27.5, 26 (1–69) ,0.0001
Data are shown as mean and median (range), except ‘risk’ (number of cases).
aPSA 12 months after radiation.
Table 3. Logistic regression analysis for biochemical failure
Odds ratio 95% CI
Initial PSA (ng/ml) 1.054 1.019–1.090
Stage
T2
a 5.25 1.325–20.803
T3 6.927 1.837–26.121
Gleason
7
b 0.462 0.128–1.666
8 0.739 0.160–3.416
Nadir PSA (ng/ml) 1.477 0.977–2.233
Radiation–nadir (months) 0.95 0.908–0.993
aReference: stage T1.
bReference: Gleason 6.
Table 4. Factors inﬂuenced biochemical failure divided by PSA-DT
PSA-DT8.3 (24) PSA-DT . 8.3 (23) P value
Initial PSA (ng/ml) 51.3, 25 (4.1–290) 33.9, 18 (6–245) 0.322
Nadir PSA (ng/ml) 3.4, 2.0 (0.2–11.2) 5.2, 1.7 (0.4–51.9) 0.47
Radiation–nadir
(months)
10.3, 9 (2–21) 18.5, 18 (5–45) 0.001
Radiation–failure
(months)
18.5, 17 (4–36) 14.3, 13 (8–55) 0.06
Data are shown as mean and median (range).
Median of PSA-doubling time (DT) (8.3 months).
Table 5. Factors inﬂuencing second biochemical failure
Second failure (10) No second failure (37) P value
Initial PSA
(ng/ml)
26.8, 15.8 (4.1–82.7) 47.4, 25.2 (5.7–290) 0.148
Nadir PSA
(ng/ml)
4.6, 3.3 (0.2–11.2) 4.2, 1.4 (0.3–51.9) 0.83
Failure PSA
(ng/ml)
10.6,.2.0 (2.6–31.9) 6.8, 4.0 (1–56.8) 0.29
Radiation–
failure
(months)
14.3, 14 (4–28) 31.7, 27 (5–55) ,0.0001
PSA-DT
(months)
4.8, 6 (0.9–11.2) 10.6, 9.6 (2.5–30.8) 0.0002
Velocity
(ng/ml/year)
25.1, 11.5 (2.7–96.5) 6.0, 3.2 (0.4–31.9) 0.09
Data are shown as mean, median and range. All data are quoted from the
ﬁrst biochemical failure.
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hormone therapy have been indicated recently (30). In the
present study, the response to hormone therapy was favorable
in general, and this may be attributable to a hormone-naı ¨ve
condition in patients. Duration of hormone therapy after bio-
chemical failure seems to be long, and this might be due to
the presence of residual cancer foci. The treatment period of
hormone therapy with radiotherapy is an issue under debate,
but it might be advisable to make treatment plans adaptable
to the individual situations of patients.
CONCLUSION
Patients with T1–T3 prostate cancer who were surgically
conﬁrmed to be N0 were treated with radiotherapy. Few bio-
chemical failures were observed in patients with low and
intermediate risks. Patients with high risk, however, showed
biochemical failure in 64%, in whom 97% of failure
occurred by 3 years after radiation. Initial and nadir PSA,
and duration between radiation and nadir were the factors for
biochemical failure. Some patients with ﬁrst failure, mostly
high risk, showed the second failure, and PSA-DT was the
factor for second failure, suggesting that patients with
second failure had rapidly growing hormone-independent
tumors. Most patients after the biochemical failure responded
well to hormone therapy, showing favorable results by
delayed hormone therapy. It is emphasized that half of
patients with high risk can be treated with radiation and lym-
phadenectomy alone.
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